Robert Maykut

1.2k total citations
36 papers, 907 citations indexed

About

Robert Maykut is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Robert Maykut has authored 36 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Physiology, 25 papers in Pulmonary and Respiratory Medicine and 15 papers in Immunology and Allergy. Recurrent topics in Robert Maykut's work include Asthma and respiratory diseases (28 papers), Allergic Rhinitis and Sensitization (15 papers) and Inhalation and Respiratory Drug Delivery (12 papers). Robert Maykut is often cited by papers focused on Asthma and respiratory diseases (28 papers), Allergic Rhinitis and Sensitization (15 papers) and Inhalation and Respiratory Drug Delivery (12 papers). Robert Maykut collaborates with scholars based in United States, Switzerland and United Kingdom. Robert Maykut's co-authors include Guy Peachey, Gregory P. Geba, Robert K. Zeldin, Allen P. Kaplan, Kusumam Joseph, Gert‐Jan Braunstahl, Panayiotis Georgiou, J Bruce, Zenon Siergiejko and Clare Peckitt and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and Allergy.

In The Last Decade

Robert Maykut

35 papers receiving 885 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Maykut United States 14 628 531 334 215 114 36 907
Mark H. Moss United States 10 1.3k 2.1× 1.1k 2.2× 192 0.6× 47 0.2× 33 0.3× 24 1.5k
Jan Holt Norway 10 141 0.2× 94 0.2× 95 0.3× 34 0.2× 21 0.2× 22 428
Joanne Kavanagh United Kingdom 13 661 1.1× 546 1.0× 163 0.5× 72 0.3× 5 0.0× 18 772
Marijke Amelink Netherlands 13 1.1k 1.8× 908 1.7× 230 0.7× 39 0.2× 6 0.1× 18 1.3k
Kathy Lampl United States 14 266 0.4× 232 0.4× 44 0.1× 54 0.3× 11 0.1× 34 742
C S Ulrik Denmark 19 1.1k 1.7× 954 1.8× 239 0.7× 21 0.1× 7 0.1× 29 1.2k
Ryan Ziemiecki United States 11 179 0.3× 168 0.3× 14 0.0× 125 0.6× 84 0.7× 28 621
Ebymar Arismendi Spain 12 245 0.4× 250 0.5× 28 0.1× 27 0.1× 22 0.2× 43 482
Marina Blanco‐Aparicio Spain 15 291 0.5× 402 0.8× 58 0.2× 20 0.1× 3 0.0× 91 624
Sabah Iqbal United States 10 204 0.3× 86 0.2× 18 0.1× 19 0.1× 194 1.7× 36 522

Countries citing papers authored by Robert Maykut

Since Specialization
Citations

This map shows the geographic impact of Robert Maykut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Maykut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Maykut more than expected).

Fields of papers citing papers by Robert Maykut

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Maykut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Maykut. The network helps show where Robert Maykut may publish in the future.

Co-authorship network of co-authors of Robert Maykut

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Maykut. A scholar is included among the top collaborators of Robert Maykut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Maykut. Robert Maykut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ratjen, Félix, Alexander Mœller, Robert Maykut, et al.. (2018). Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study. Journal of Cystic Fibrosis. 18(1). 78–85. 28 indexed citations
2.
3.
Braunstahl, Gert‐Jan, et al.. (2013). The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respiratory Medicine. 107(8). 1141–1151. 156 indexed citations
4.
Fiel, Stanley B., Samya Z. Nasr, Robert Wan, et al.. (2013). Rate of Hospitalizations Due to Respiratory Events With Tobramycin Inhalation Powder in Patients With Cystic Fibrosis. CHEST Journal. 144(4). 756A–756A. 2 indexed citations
5.
Heuerding, S., et al.. (2013). 72 Inspiratory flow characteristics of the T-326 dry powder inhaler (DPI) in CF patients. Journal of Cystic Fibrosis. 12. S66–S66. 5 indexed citations
6.
Siergiejko, Zenon, et al.. (2011). Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Current Medical Research and Opinion. 27(11). 2223–2228. 61 indexed citations
7.
Bousquet, Jean, Zenon Siergiejko, Marc Humbert, et al.. (2011). Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 66(5). 671–678. 137 indexed citations
8.
Braunstahl, Gert‐Jan, et al.. (2011). Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Current Medical Research and Opinion. 27(4). 761–767. 16 indexed citations
9.
Molimard, Mathiéu, Roland Buhl, Robert Niven, et al.. (2010). Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data. Respiratory Medicine. 104(9). 1381–1385. 65 indexed citations
10.
Dean, Bonnie B., et al.. (2010). Uncontrolled Asthma Among Children: Impairment in Social Functioning and Sleep. Journal of Asthma. 47(5). 539–544. 28 indexed citations
11.
Dean, Bonnie B., et al.. (2010). Uncontrolled asthma: assessing quality of life and productivity of children and their caregivers using a cross-sectional Internet-based survey. Health and Quality of Life Outcomes. 8(1). 96–96. 78 indexed citations
12.
Maykut, Robert, Robert S. Zeiger, & Mark A. Brown. (2010). Asthma in Pediatric Patients: Unmet Need and Therapeutic Options. Clinical Pediatrics. 49(10). 915–930. 2 indexed citations
13.
Kaplan, Allen P., Kusumam Joseph, Robert Maykut, Gregory P. Geba, & Robert K. Zeldin. (2008). Treatment of chronic autoimmune urticaria with omalizumab. Journal of Allergy and Clinical Immunology. 122(3). 569–573. 200 indexed citations
14.
Maykut, Robert, Farid Kianifard, & Gregory P. Geba. (2008). Response of Older Patients with IgE-Mediated Asthma to Omalizumab: A Pooled Analysis. Journal of Asthma. 45(3). 173–181. 34 indexed citations
15.
Massanari, Marc, Patricia Sacco, Farid Kianifard, Robert Maykut, & Robert K. Zeldin. (2008). Addition of Omalizumab Improved Functional Health Status in Patients With Impaired Quality of Life Associated With Moderate-Severe Persistent Allergic Asthma. Journal of Allergy and Clinical Immunology. 121(2). S154–S154. 1 indexed citations
16.
Milgrom, Henry, Marc Massanari, Robert Maykut, et al.. (2007). OMALIZUMAB IMPROVES TREATMENT EFFECTIVENESS OF CHILDREN AND ADOLESCENTS WITH MODERATE-SEVERE PERSISTENT IGE-MEDIATED ASTHMA AND REDUCES SCHOOL ABSENTEEISM. CHEST Journal. 132(4). 483B–483B. 1 indexed citations
17.
Pollard, S., Robert Maykut, Marc Massanari, et al.. (2007). Effect of Omalizumab on Measures of Control in Adolescents with Moderate-Severe Persistent Asthma. Journal of Allergy and Clinical Immunology. 119(1). S10–S10. 1 indexed citations
18.
Busse, William W., Helen Fox, K. Surrey, Robert Maykut, & Colin Reisner. (2006). Clinically Relevant Improvements in Asthma-Related Quality of Life in Patients Receiving Omalizumab as Add-On Therapy. Journal of Allergy and Clinical Immunology. 117(2). S8–S8. 1 indexed citations
19.
Massanari, Marc, Robert Maykut, Robert K. Zeldin, Farid Kianifard, & Gregory P. Geba. (2006). ADDITION OF OMALIZUMAB IMPROVES LUNG FUNCTION AND TREATMENT EFFECTIVENESS IN PATIENTS WITH MODERATE-SEVERE PERSISTENT ALLERGIC ASTHMA INADEQUATELY CONTROLLED WITH INHALED STEROIDS AND LONG-ACTING BETA-AGONISTS. CHEST Journal. 130(4). 109S–109S. 2 indexed citations
20.
Maykut, Robert, Marc Massanari, Farid Kianifard, et al.. (2005). OMALIZUMAB IMPROVES SYMPTOMS AND REDUCES RESCUE BETA-AGONIST USE IN OLDER PATIENTS WITH UNCONTROLLED ASTHMA. CHEST Journal. 128(4). 243S–243S. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark H. Moss Breakdown of academic impact, for papers by Jan Holt Breakdown of academic impact, for papers by Joanne Kavanagh Breakdown of academic impact, for papers by Marijke Amelink Breakdown of academic impact, for papers by Kathy Lampl Breakdown of academic impact, for papers by C S Ulrik Breakdown of academic impact, for papers by Ryan Ziemiecki Breakdown of academic impact, for papers by Ebymar Arismendi Breakdown of academic impact, for papers by Marina Blanco‐Aparicio Breakdown of academic impact, for papers by Sabah Iqbal
Rankless by CCL
2026